A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

Clinical trial NCT04708418 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04708418
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Clinical Stage III Cutaneous Melanoma AJCC v8 Melanoma of Unknown Primary Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Pathologic Stage IIID Cutaneous Melanoma AJCC v8 Recurrent Cutaneous Melanoma

Start date: 2021-10-15
Primary completion: 2026-12-31
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.